The pharmaceutical industry is rapidly recognising the advantages offered by ddRNAi technology for human applications, and this is expected to result in increasing global demand for related materials
Promega has recently acquired a worldwide exclusive licence to develop, sell and distribute DNA-directed RNAi (ddRNAi) products based upon proprietary technology developed by the Australian company Benitec.
RNAi is a relatively new research area, and one that promises to provide great opportunities in the field of gene function.
More specifically, ddRNAi is a precise and proven process for silencing any gene in any cell of any multicellular organism.
It therefore can be used in mapping cellular pathways, selecting suitable pharmaceutical targets and developing novel gene therapies.
Promega will develop novel tools aimed at facilitating the use of RNAi for research into cancer, autoimmune disorders, and chronic degenerative viral infections including HIV and hepatitis C.
Benitec will transfer know-how of its ddRNAi products to Promega.
In return, Benitec will receive a licence fee and future royalties based on sales and issuance of its worldwide patent portfolio.
The pharmaceutical industry is rapidly recognising the advantages offered by this ddRNAi technology for human applications, and this is expected to result in increasing global demand for related materials and products. Promega's considerable experience in the practical implementation of biotechnology discoveries means that it is ideally suited to accelerate and expand the development of ddRNAi constructs as routine tools.
